Genmab A/S (GMAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
GMAB POWR Grades
- GMAB scores best on the Sentiment dimension, with a Sentiment rank ahead of 85.96% of US stocks.
- The strongest trend for GMAB is in Quality, which has been heading down over the past 179 days.
- GMAB ranks lowest in Momentum; there it ranks in the 4th percentile.
GMAB Stock Summary
- With a price/sales ratio of 18.23, Genmab A has a higher such ratio than 92.26% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.11 for Genmab A; that's greater than it is for only 8.84% of US stocks.
- As for revenue growth, note that GMAB's revenue has grown -22.47% over the past 12 months; that beats the revenue growth of only 6.69% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Genmab A are GLPG, VALN, HIMX, IMMP, and ERYP.
- GMAB's SEC filings can be seen here. And to visit Genmab A's official web site, go to www.genmab.com.
GMAB Stock Price Chart Interactive Chart >
GMAB Price/Volume Stats
|Current price||$31.08||52-week high||$49.07|
|Prev. close||$30.43||52-week low||$27.42|
|Day high||$31.11||Avg. volume||659,081|
|50-day MA||$34.48||Dividend yield||N/A|
|200-day MA||$38.83||Market Cap||20.43B|
Genmab A/S (GMAB) Company Bio
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.
Most Popular Stories View All
GMAB Latest News Stream
|Loading, please wait...|
GMAB Latest Social Stream
View Full GMAB Social Stream
Latest GMAB News From Around the Web
Below are the latest news stories about Genmab A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; February 25, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 25, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 190,202 restricted stock units to five members of management and employees of the company as well as the company's subsidiaries and 175,595 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. T
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
BOTHELL, Wash., & COPENHAGEN, Denmark, February 24, 2022--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Media ReleaseCOPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022 Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022 Multidisciplinary Head and Neck Cancers Symposium Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the hea
Company Announcement Genmab A/S to hold Annual General Meeting on Tuesday March 29, 2022 COPENHAGEN, Denmark; February 24, 2022 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Tuesday, March 29, 2022, at 2:00 PM CEST at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directorsis attached. About Genmab Genmab is an international biotechnology company with
GMAB Price Returns